Reaction
Tumour Excision reporting signals
As of the last recalculation, Tumour Excision appears in 792 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is IMATINIB MESYLATE (PRR 39.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Imatinib Mesylate | 40 | 39.6 | 39.7 |
| Imatinib | 18 | 27.4 | 27.4 |
| Lanreotide Acetate | 8 | 27.1 | 27.1 |
| Avapritinib | 12 | 26.4 | 26.5 |
| Pazopanib Hydrochloride | 18 | 17.9 | 17.9 |
| Niraparib | 11 | 13.2 | 13.2 |
| Brivaracetam | 4 | 11.7 | 11.7 |
| Temozolomide | 9 | 11.3 | 11.3 |
| Ivacaftor | 3 | 10.0 | 10.0 |
| Bimekizumab | 7 | 8.7 | 8.7 |
| Trifluridine And Tipiracil | 3 | 7.4 | 7.4 |